IP Library Granted Patent US 7,867,498
Granted Patent B2
US 7,867,498 · App. 12/383,545 · Granted Jan 11, 2011

Polypeptide carrier protein

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,867,498
App. No.
12/383,545
Granted
Jan 11, 2011
Kind
B2
Abstract

The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.

Claims (8)

1. A carrier protein comprising at least five different CD4+ T cell epitopes, wherein the CD4+ T cell epitopes are CD4+ T cell epitopes from tetanus toxin, Plasmodium falciparum circumsporozite protein, hepatitis B surface antigen, hepatitis B nuclear core protein, influenza matrix protein, influenza haemagglutinin, diphtheria toxoid, diphtheria toxin mutant CRM197, group B Neisseria meningitidis outer membrane protein complex, pertussis toxin or heat shock protein 70, wherein said carrier protein lacks B-cell and T-suppressor epitopes.

2. The carrier protein of claim 1 , wherein the CD4+ T cell epitopes are selected from P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, influenza haemagglutinin (HA), HbsAg, influenza matrix (MT) and hsp70 CD4+ T-cell epitopes.

3. The carrier protein of claim 1 , wherein the carrier protein comprises P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, influenza haemagglutinin (HA), HbsAg, and influenza matrix (MT) CD4+ T-cell epitopes.

4. The carrier protein of claim 1 , wherein the carrier protein comprises P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, influenza haemagglutinin (HA), HbsAg, influenza matrix (MT) and hsp70 CD4+ T-cell epitopes.

5. The carrier protein of claim 1 , wherein the carrier protein comprises P23TT, P32TT, P21TT, PFT3, P30TT, and P2TT CD4+ T-cell epitopes.

6. The carrier protein of claim 1 , wherein the CD4+ T cell epitopes are human CD4+ T-cell epitopes.

7. The carrier protein of claim 1 , wherein the carrier protein comprises one or more of the N6, N10 or N19 proteins.

8. The carrier protein of claim 1 , wherein the carrier protein comprises P23TT, P32TT, P21TT, PFT3, P30TT, P2TT, HBVnc, influenza haemagglutinin (HA), and HbsAg CD4+ T cell epitopes.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2011
From: CHIRON S.P.A.
To: CHIRON SRL
Reel/Frame 025627/0505 →
CHANGE OF NAME Recorded Nov 16, 2010
From: CHIRON SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 025379/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2010
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 025379/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2010
From: RAPPUOLI, RINO; GRANDI, GUIDO
To: CHIRON SPA
Reel/Frame 025052/0388 →
Priority Claims (1)
GB 0908932.9 · Apr 27, 1998 · national
Continuity (3)
Division 1103063500 · Jan 6, 2005
Continuation 0967418300
Related Publication 20090227770A1 · Sep 10, 2009